Biosimilars – Emerging Biosimilars – Oncology: Zarxio Launch Tracking (US) Wave 3

Biosimilars | Emerging Biosimilars | Oncology: Zarxio Launch Tracking (US) Wave 3 is the third and final installment in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s Neupogen and the first biosimilar to launch in the United States. Medical oncologists and hematology-oncologists in the United States were surveyed to assess their awareness and perception of Zarxio, uptake of the biosimilar over time, Zarxio's effect on other G-CSFs, and promotional activity related to Zarxio and its competitors. Formulary coverage and restrictions associated with Zarxio and other G-CSFs were also evaluated.

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology: Zarxio Launch Tracking (US) Wave 3
    • Key Findings
      • Zarxio Awareness and Promotional Activity for G-CSFs
      • Who Are Zarxio Prescribers and Nonprescribers?
      • Differences Between Zarxio Prescriber and Nonprescriber Profiles
      • Who Is the Zarxio Patient?
      • Zarxio-Treated Patients by Indication
      • Trends in Zarxio Uptake
      • Patient Share of Filgrastim Products by Practice Type
      • Quarterly U.S. Sales of Short-Acting G-CSFs
    • Benchmarking Zarxio Launch Success versus Other New Products
      • Benchmarking Zarxio Launch Success Versus Other New Products
    • Formulary Analysis
      • Introduction
        • U.S. Payer-Reported Coverage of G-CSFs
      • Formulary Coverage of G-CSFs
        • G-CSF Coverage Among Commercial Plans
        • G-CSF Coverage Among Medicare Plans
      • Zarxio Formulary Coverage Compared with Neupogen
        • Zarxio Commercial and Medicare Coverage Compared with Neupogen
      • Granix Formulary Coverage Compared with Neupogen
        • Granix Commercial and Medicare Coverage Compared with Neupogen
      • Changes in Formulary Status of G-CSFs
        • Changes in Formulary Status October 2015-September 2016: Commercial
        • Changes in Formulary Status October 2015-September 2016: Medicare
    • Zarxio Awareness and Perceptions
      • Unaided Awareness of Biologics for Treatment/Prevention of Chemotherapy-Induced Neutropenia
        • Biologics Recalled for Chemotherapy-Induced Neutropenia
      • Level of Familiarity with Biosimilars and Zarxio
        • Level of Familiarity with Biosimilars
        • Level of Familiarity with Zarxio
      • Physician Perception of Indications in Which Zarxio Was Studied
        • Indications in Which Physicians Believe Zarxio Was Clinically Studied Prior to Approval
      • Physician Perception of Zarxiou2019s Approved Indications
        • Indications Physicians Believe Zarxio Is Approved to Treat
      • Physician Perception of Indications Zarxio Should Be Approved to Treat
        • Indications Physicians Believe Zarxio Should Be Approved to Treat
    • Zarxio Trial and Use
      • Patients Prescribed Zarxio
        • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Who Have Received Zarxio
        • Number of Hematology-Oncology Patients Who Have Received Zarxio
        • Healthcare Coverage for Zarxio-Treated Patients
        • Healthcare Coverage for Neutropenia Patients
        • Proportion of Zarxio-Treated Patients Who Were G-CSF-Naive or Switched from Another G-CSF
        • Current G-CSF Patient Share
        • Current Patient Share of Long- and Short-Acting G-CSFs by Prescriber Status
      • Prescribers' Experience of Zarxio
        • Proportion of Oncologists Who Have Prescribed Zarxio to at Least One Patient
        • Reasons for Choosing to Prescribe Zarxio
        • Prescribers' Perception of Zarxiou2019s Similarity to Neupogen
        • Reported Differences Between Zarxio and Neupogen
        • Overall Level of Satisfaction with Zarxio
        • Perceived Discount of Zarxio Compared with Neupogen Net Cost
        • WAC per Unit and Discount Relative to Neupogen for Filgrastim Products
        • WACs per mcg and Medicare Part B Payment Limits for Filgrastim Products
      • Reasons for Not Prescribing Zarxio
        • Oncologists' Reasons for Not Prescribing Zarxio
    • External Factors Affecting Use
      • Factors That Could Increase Use of Zarxio
        • Factors That Would Encourage Use or Increase Use of Zarxio
      • Sources of Pressure or Recommendations to Use Zarxio
        • Sources of Pressure for the Use of Zarxio Instead of Other G-CSF Brands
      • Predicted Uptake of Zarxio by Healthcare Coverage
        • Predicted Variability in Zarxio Uptake Depending on Patientsu2019 Healthcare Coverage
        • Reasons for Rapid Uptake of Zarxio
      • Rate of Acceptance of Zarxio by Patients
        • Percentage of Patients Who Accepted Zarxio When Proposed
        • Percentage of Oncologists Who Have Never Proposed Use of Zarxio
      • Opinions on Nonproprietary Names for Biosimilars
        • Oncologists' Opinions on Nonproprietary Names for Biosimilars
    • Promotional Activity
      • Most Recent Contact with Sales Representatives
        • Most Recent Contact with Medical Sales Representatives for Zarxio and Competitors
      • Topics of Discussion with Medical Representatives
        • Topics Discussed with Medical Representatives
    • Future Use of Biosimilars
      • Zarxio's Influence on Willingness to Use Other Biosimilars
        • Likelihood of Prescribing Other Biosimilars as a Result of Zarxio Use: Medical Oncologists
        • Likelihood of Prescribing Other Biosimilars as a Result of Zarxio Use: Hematology-Oncologists
      • Likelihood of Prescribing Different Filgrastim Biosimilars
        • Likelihood of Prescribing Other Filgrastim Biosimilars
      • Future Patient Share Expectations for G-CSFs
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Unavailable: Medical Oncologists
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Unavailable: Hematology-Oncologists
        • Future G-CSF Patient Share If Pegfilgrastim Biosimilars Are Available
        • Future Patient Share of Long- and Short-Acting G-CSFs by Prescriber Status
        • Future Patient Share of Long- and Short-Acting G-CSF Biosimilars by Prescriber Status
    • Appendix
      • Background on the U.S. G-CSF Market
        • Overview
        • Product Information: Short-Acting G-CSFs
        • Approved Indications for Short-Acting G-CSFs in the United States
        • Product Information: Long-Acting G-CSFs
        • Approved Indications for Long-Acting G-CSFs in the United States
        • G-CSF Market News
        • Assumptions Supporting U.S. Launch Date Estimates for Future G-CSF Biosimilars
        • Clinical Trial Information for Zarxio
      • Methodology and Objectives
        • Objectives
        • Methodology
        • Number of Study Participants
        • Significance Testing in This Study
      • Respondent Demographics
        • Respondents' Practice Location
        • Distribution of Respondents by Region
        • Years in Clinical Practice
        • Practice Type
        • Number of Patients Receiving Myelosuppressive Chemotherapy Managed Per Month: Medical Oncologists
        • Number of Adult Cancer Patients Under Management per Month: Hematology-Oncologists
        • Number of Pediatric Cancer Patients Under Management per Month: Hematology-Oncologists
        • Drugs Prescribed by Medical Oncologists
        • Drugs Prescribed by Hematology-Oncologists
      • Table of Abbreviations